Approach

Summary

Licensing status

Publication and contact information

Disease models

DNA sequencing of drug-resistant mammalian cells and clustered, regularly interspaced short palindromic repeats (CRISPR)-Cas9 genome editing to identify drug targets

Cell culture studies suggest high-throughput sequencing and CRISPR-Cas9 genome editing can be combined to rapidly validate drug targets. The approach uses high-throughput sequencing to identify mutations in drug-resistant clones and a CRISPR-Cas9 genome editing approach called DrugTargetSeqR to confirm the roles of the mutations in resistance. In cancer cell lines, the combination approach correctly identified the targets for two compounds in clinical trials. In another human cancer cell line, a related method correctly identified the targets and their resistance-conferring mutations for two toxic compounds. Next steps include automating the workflow of DrugTargetSeqR.

SciBX 7(28); doi:10.1038/scibx.2014.840
Published online July 24, 2014

For findings from both studies, DrugTargetSeqR patented; available for licensing from The Rockefeller University Office of Technology Transfer

Kasap, C. et al. Nat. Chem. Biol.; published online June 15, 2014;
doi:10.1038/nchembio.1551
Contact: Tarun M. Kapoor, The Rockefeller University, New York, N.Y.
e-mail:

kapoor@rockefeller.edu

Smurnyy, Y. et al. Nat. Chem. Biol.; published online June 15, 2014;
doi:10.1038/nchembio.1550
Contact: Yan Feng, Novartis Institutes for BioMedical Research, Cambridge, Mass.
e-mail:

yan.feng@novartis.com